MRC Clinical Trials Unit at UCL
Institute of Clinical Trials & Methodology
90 High Holborn
2nd Floor
London
WC1V 6LJ
Email. mrcctu.focus4@ucl.ac.uk
FOCUS4 is now closed to recruitment.
FOCUS4 aimed to register 2400 and randomise at least 1536 patients from over 100 hospitals across the whole of the UK. Previous research has shown that this number of hospitals can screen about 70 patients per month and the distribution of molecular cohorts will be similar to those in Table 1 below. Therefore, the aim was to recruit for 4-5 years to reach our target recruitment of at least 1536 patients.
Table 1 | 70 screened patients per month | |||
---|---|---|---|---|
Molecular cohort | Prevalence | Randomised patients/mth | Total over 4 years | Total over 5 years |
Total | 100% | 32 | 1536 | 1920 |
BRAF mutation | 8% | 2.6 | 125 | 156 |
PIK3CA mutation and/or PTEN loss | 30% | 9.6 | 461 | 576 |
KRAS or NRAS mutation | 33% | 10.6 | 509 | 636 |
EGFR dependent | 27% | 8.6 | 413 | 516 |
Non-stratified | 2% | 0.6 | 28 | 36 |
FOCUS4
MRC Clinical Trials Unit at UCL
Institute of Clinical Trials & Methodology
90 High Holborn
2nd Floor
London
WC1V 6LJ
Email. mrcctu.focus4@ucl.ac.uk